key: cord-1044476-ix00r93b
authors: Marengoni, Alessandra; Zucchelli, Alberto; Vetrano, Davide Liborio; Armellini, Andrea; Botteri, Emanuele; Nicosia, Franco; Romanelli, Giuseppe; Beindorf, Eva Andrea; Giansiracusa, Paola; Garrafa, Emirena; Ferrucci, Luigi; Fratiglioni, Laura; Bernabei, Roberto; Onder, Graziano
title: Beyond chronological age: Frailty and multimorbidity predict in-hospital mortality in patients with coronavirus disease 2019
date: 2020-11-20
journal: J Gerontol A Biol Sci Med Sci
DOI: 10.1093/gerona/glaa291
sha: 4c08b514c75f1e162bf5469d089ae91c291663a8
doc_id: 1044476
cord_uid: ix00r93b

BACKGROUND: We evaluated whether frailty and multimorbidity predict in-hospital mortality in patients with COVID-19 beyond chronological age. METHODS: 165 patients admitted from March 8th to April 17th, 2020, with COVID-19 in an acute geriatric ward in Italy were included. Pre-disease frailty was assessed with the Clinical Frailty Scale (CFS). Multimorbidity was defined as the co-occurrence of ≥2 of these in the same patient. The hazard (HR) of in-hospital mortality as a function of CFS score and number of chronic diseases in the whole population and in those aged 70+ years were calculated. RESULTS: Among the 165 patients, 112 were discharged, 11 were transferred to intensive care units and 42 died. Patients who died were older (81.0 vs. 65.2 years, p<0.001), more frequently multimorbid (97.6 vs. 52.8%; p<0.001) and more likely frail (37.5 vs. 4.1%; p<0.001). Less than 2.0% of patients without multimorbidity and frailty, 28% of those with multimorbidity only and 75% of those with both multimorbidity and frailty died. Each unitary increment in the CFS was associated with a higher risk of in-hospital death in the whole sample (HR=1.3; 95%CI=1.05-1.62) and in patients aged 70+ years (HR=1.29;95%CI=1.04-1.62), whereas the number of chronic diseases was not significantly associated with higher risk of death. The CFS addition to age and sex increased mortality prediction by 9.4% in those aged 70+ years. CONCLUSIONS: Frailty identifies patients with COVID-19 at risk of in-hospital death independently of age. Multimorbidity contributes to prognosis because of the very low probability of death in its absence.

Clinical manifestations of coronavirus disease 2019 (COVID-19) vary greatly ranging from asymptomatic infection to severe and sometimes fatal respiratory failure 1 . Similar to other previously isolated coronaviruses responsible for the severe acute respiratory syndrome (SARS) and the Middle East respiratory syndrome (MERS) 2,3 , severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) can cause interstitial pneumonia 4 . The case-fatality rate has been reported to steeply increase with age worldwide, from 4.9% in the 0-59 years to 9.5% in the 60-69 years, reaching 25.2% in the 90+

year-old 5 . In accordance with the Italian National Institute of Health surveillance system, persons who died by COVID-19 were more frequently older, males, and presented a mean number of 2.7 preexisting chronic diseases. Overall, 74% of the deceased individuals had multimorbidity (i.e., two or more chronic diseases) 6 . Hypertension, chronic obstructive pulmonary disease (COPD), malignancy, chronic kidney disease, cardiovascular disease, and diabetes mellitus were the most common comorbidities among hospitalised persons affected by COVID-19 7 , and patients with pre-existing cardiovascular and metabolic conditions have the greatest risk of adverse outcomes 8 .

Along with its burden on the health and well-being of affected individuals, the most severe cases of COVID-19 are currently overloading the healthcare systems of several countries, which are striving to adapt their actions to the new condition. A prompt and reliable identification of patients affected by COVID-19 at higher risk of death may direct clinical management and difficult decision-making.

Recommendations provided so far by health agencies suggest that patients' biological agerather than chronologicalmust steer clinical decisions 9,10,11 . However, instruments available to assess biological age are not yet ready for clinical applications. As a result, chronological age has been used in decision-making, such as intensive care unit (ICU) admissions, without solid evidence supporting such decisions.

A c c e p t e d M a n u s c r i p t 5 Frailty, a state of increased vulnerability caused by reduced homeostasis in several systems 12 and multimorbidity, the simultaneous presence of multiple chronic conditions in the same individuals 13 , could be used as surrogate measures of biological aging, as they track the rate of decline in health and function with aging, and, independent of chronological age, their presence has been associated with a number of unfavourable outcomes including hospitalization, disability and mortality [14] [15] [16] . In the general population, as well as in individuals admitted to ICUs, the impact of frailty is clear even in persons without multimorbidity 17, 18 . Frailty predicts mortality in the adult population 19 , is associated with lower probability of recovery in elderly persons hospitalized with influenza and acute respiratory illness (increasing the odd of death during the 30 days post-discharge) 20 and is a negative prognostic predictor in patients affected by HIV 21 . Although frailty and multimorbidity can overlap, approximately one fourth of persons with multimorbidity do not have frailty 22 , suggesting that frailty and multimorbidity bring complementary information in the patients' assessment.

The aim of this study was to evaluate whether frailty and multimorbidity predict in-hospital mortality beyond chronological age among patients with COVID-19 admitted to a tertiary care hospital in Italy.

This is a retrospective observational study including 171 consecutive patients with a diagnosis of COVID-19 admitted to the acute geriatric unit of the Civili Hospital in Montichiari (Brescia, Northern Italy) from March 8 th to April 17 th , 2020. At the onset of the COVID-19 emergency, the Montichiari hospital was designated as COVID-19 special hospital in the Lombardy region and the geriatric medicine unit of the hospital was open to both younger and older adults affected by the disease.

Patients were admitted to the geriatric ward if they had signs or symptoms of COVID-19, independently of their age. Of the 171 patients, 6 were not included in this study due to a high amount of missing information in their medical charts. All the remaining 165 patients were followed up for the whole hospitalization in the acute geriatric ward.

A c c e p t e d M a n u s c r i p t 6 By the 17th of April, all patients were either discharged (N = 112 -67.9%), transferred to the ICU (ICUs across the whole Lombardy or other regions) (N = 11-6.7%) or dead (N = 42 -25.4%).

Patients were discharged if they displayed peripheral oxygen saturation >94% in ambient air, a respiratory frequency lower than 22 times per minute and had no fever for 48 hours. The decision to discharge a patient was not affected by the paucity of resources, but always in keeping of the clinical conditions of the individual patient The decision upon ICU-transferal was made by critical care physicians, who evaluated the vital parameters, blood exams and respiratory distress twice daily or upon request of the geriatric ward physician. Patients transferred to the ICU were younger (59.5 years, SD=16.1); all of them were non-frail, 5 (45.4%) had multimorbidity and the median number of drugs prescribed at home was 0 (IQR 3).

Nasal and pharyngeal swab samples were collected at hospital admission by trained nurses and total SARS-Cov-2 RNA was extracted for testing. COVID-19 cases were identified by reverse transcriptase-polymerase chain reaction (RT-PCR) assay for SARS-Cov-2 RNA. A small number of cases with a negative or undetermined test (N = 11) were considered to be infected by SARS-Cov-2 based on the computed tomography of the chest and the highly suggestive clinical characteristics 23 . A recent systematic review of the literature showed that false-negative test results may occur in up to 20% to 67% of patients affected by COVID-19 24 .

The study was approved by the Ethical Committee of the Brescia County (Italy).

Information on age, sex, education and living arrangement were collected. Education was categorized into primary (5 years of schooling or less) and secondary education (≥6 years). Clinical and laboratory characteristics and outcome data were obtained from medical records and anonymously aggregated.

The following data were collected: smoking history, number of chronic diseases among a pre-defined and validated list of 60 diseases, 13 multimorbidity (defined as 2+ co-occurring diseases in the same A c c e p t e d M a n u s c r i p t 7 patient), number of drugs before hospital admission, symptoms and signs of infection (fever, cough, headache, dyspnoea, weakness, ageusia, olfactory impairment, gastrointestinal problems).

Frailty was assessed at hospital admission by a geriatrician who collected information about the preinfection health status of the patient. Such information was collected directly from the patient if he/she was not cognitively impaired and affected by moderate disease. If the patient was cognitively impaired or severely ill, this information was collected from a proxy/caregiver. The Clinical Frailty Scale (CFS) was employed to assess frailty: the CFS is an ordinal 9-point scale in which the assessor makes decisions about the degree of frailty from clinical data 25 . The patients are scored from 1 "very fit" to 9 "terminally ill", with a score of 6 or more being indicative of moderate to severe frailty.

According to the CFS, a patient is non to mildly frail for scores <6 (1 being robust and physically active to 5 being dependent in instrumental activities of daily living such as shopping and managing medications), moderately frail from score 6 to 7 (6 being dependent in all the outdoor activities and bathing and 7 being dependent in personal care) and severely frail from scores 8 to 9 (8 being dependent in all basic activities of daily living and 9 being terminally ill). In the case of cognitive impairment or severe COVID-19 at admission, information regarding frailty was asked to a proxy/caregiver. Laboratory data comprised of a complete blood count, white blood cells count, O2, CO2, pH blood gas test, and a C-reactive protein (CRP) test. Pharmacological treatments during hospitalization were M a n u s c r i p t 9

As showed in Table 1 , patients were 69.3 years old (SD 14.5) on average and 55.1% were 70-year-old or older; 60.6% were males and 49.7% had primary education. The median duration of symptoms before hospital admission was 7 days and the median length of hospital stay was 10 days (IQR 7-17).

Overall, 28.5% of patients had an arterial oxygen saturation<90% at hospital admission. The median number of chronic diseases was 2 (IQR 1-4) and 64.2% of patients were affected by multimorbidity.

The median CFS score was 2 (IQR 2-4) and 87.7% of patients had a CFS score < 6. Patients who died were more likely to be older (p<0.001) and had lower educational attainment (p=0.001). The percentage of patients with arterial oxygen saturation<90% at hospital admission was 60.5% in those who died versus 17.0% in those who did not (p<0.001). The median C-reactive protein was higher in those who died (p<0.001). The median number of chronic co-existing diseases was higher among those who died (3 vs. 2, p<0.001). Thirty-seven percent of patients who died vs 4.1% of those who did not had a CFS score ≥ 6.

Insert Table 1 here Table 2 and 3 show Cox regression models reporting the hazard ratios (HR) for death and the cstatistics derived from survival analyses associated with CFS score and number of chronic diseases adjusted for age, sex, and education in the whole sample and in patients aged 70+ years (N = 91), respectively. Each unit increase in CFS score was associated with increased in-hospital death both in the whole sample and among older individuals, whereas each unit increase in the number of chronic diseases was not significantly associated with higher risk of in-hospital mortality. The addition of the CFS improved the model's goodness of fit by 9.4% in the subsample of patients aged 70 years and older: the model containing CFS has a 9% increased probability to assign a higher risk of death to those who actually died during the hospitalization, in comparison to the model based on age, sex, and education only.

A c c e p t e d M a n u s c r i p t 10 Figure 1 displays Kaplan Meier survival plots for patients with no multimorbidity and no frailty as the reference group (n=57median hospital length of stay = 11), those with multimorbidity only (n=85median hospital length of stay = 11) and those with multimorbidity and frailty (n=20median hospital length of stay = 6.5). In our study, frailty always co-occurred with multimorbidity. One point eight percent of patients without multimorbidity and frailty, 28% of those with multimorbidity only and 75% of those with both multimorbidity and frailty died during hospitalization. 

In hospitalized patients with COVID-19, higher CFS scores were associated with mortality, independently of chronological age. Moreover, the CFS appeared to improve the prediction of death beyond chronological age among those aged 70+ years.

We used data collected during this emergency period to test the hypothesis that patients admitted to the hospital had some clinical characteristics that differentiated those who survived to the study's end from those who died. Studies in China have reported that patients with COVID-19 who suffered adverse outcomes were older than those who recovered, and that some specific chronic conditions were more prevalent in those who died 1, 8, 28, 29 . The findings of our study align with such previous A c c e p t e d M a n u s c r i p t 11 reports, also adding new insight into the role of multimorbidity and frailty, independent of age as risk factors for mortality in those with COVID-19.

In our study, patients with CFS ≥ 6 were 9 times more likely to die during the hospitalization than those with lower scores. Of note, the CFS alone predicted in-hospital death with a discriminative ability of 88%. Currently, there is no internationally recognized standard definition and operationalization of frailty given its complex pathophysiology. The main reason for that is that the underlying mechanisms of frailty are still under investigation. At the same time, due to the urgency to have tool spendable in clinical practice, a high number of frailty definitions have been proposed in the last two decades, showing fair to good validity 30 . We found that 12% of patients could be defined as moderately or severely frail, according to the CFS, which is the clinical tool suggested by the NICE guidelines for the assessment of older patients affected by COVID-19 infection 11 . The CFS has shown a discriminative ability comparable to the Frailty Index 25 which is a model of accumulation of deficits, such as diseases and disability. Further, in patients admitted to a geriatric ward, the CFS and the Fried frailty phenotype 31 were equally suitable for differentiating between patients who died due to any cause from those who survived during follow-up 32 . Compared to other frailty scales, the CFS has the specific strength that it has been validated as an adverse outcome predictor in hospitalised older people 33, but, on the other hand, it is strongly tangled with the presence of disability, especially for higher CFS scores. Finally, the CFS is timesaving, especially when applied by a trained physician such as a geriatrician. The latter characteristic was very important during the emergency of COVID-19. A recent scoping review showed that five out of 6 studies on frailty assessment in COVID-19 used the CFS to assess frailty 34 . Subsequent to this review a large study mostly based on data from the UK was published showing that frailty measured by the CFS was strongly associated with mortality in hospitalized patients aged 61 years and older 35 . A c c e p t e d M a n u s c r i p t 12 Central to the frailty concept is the multisystem involvement, including dysregulation of neuromuscular, endocrine, and immune systems. The age-related decline in immune function is well documented and it can contribute to frailty as well as to an increased susceptibility to acute and chronic diseases; aging and frailty lead to an imbalance between stressors and stress-buffering mechanisms that causes loss of compensatory reserve. In particular, changes in the innate immunity could enhance a pro-inflammatory state which is a fundamental component of frailty 36, 37 .

In a systematic review of the literature, frailty and pre-frailty were associated with higher inflammatory parameters, such as C-reactive protein, interleukin-6, elevated white blood cell and fibrinogen levels 38 . Further, in older adults, a reduced chemotaxis with an inefficient neutrophil migration may induced greater tissue damage and secondary systemic inflammation 39 that, among changes in T-cells function, may impair the overall immune response of the organism. Thus, in COVID-19, frailty is likely to be a good clinical marker of a substrate sensitive to infections, and to enhance the multiorgan involvement of the infection itself 40, 41 as well as the dysregulated inflammatory response 1, 42 . All the reasons above may explain the strong association between frailty and mortality found in our and other studies. Whereas inflammatory dysregulation may well account for the link between frailty and COVID-19 mortality in older persons, other hypotheses may apply to middle-aged adults. In fact, frailty has a strong relationship with sarcopenia and malnutrition 36 which are not exclusive of older people and both conditions have been associated with poorer outcomes in adult affected by COVID-19 43 . However, due to the low number of deaths in people aged less than 65 years in this study, conclusions about the utility of the CFS in middle-aged persons cannot be drawn from our results and we cannot recommend its use in this part of the population.

Our study adds to the previous literature as we elucidated both the role of frailty measured by the CFS and multimorbidity. As demonstrated in an Italian case series by Onder et al, multimorbidity was found in three quarters of the individuals who died from COVID-19 6 . Indeed, the proportion of persons with multimorbidity increases with age 13 , as well as the case-fatality rate of COVID-19, reported thus far 5 . However, given the high prevalence of multimorbidity in the older population, this would not directly imply an effect of multimorbidity on poor prognosis in COVID-19. Interestingly, A c c e p t e d M a n u s c r i p t 13 in our study, those without multimorbidity were 20 times more likely to survive during hospitalization than those affected by 2+ chronic diseases. In previous studies conducted in the community, it was estimated that about one quarter of persons affected by multimorbidity are not frail, 22 suggesting that frailty and multimorbidity capture different aspects of health. Previous studies carried out before the COVID-19 pandemic showed that frailty indices and multimorbidity have different accuracy in predicting mortality in older adults 44 . Our findings on the different specificity and sensitivity of frailty and multimorbidity in predicting mortality in hospitalized patients with COVID-19 reinforce this assumption.

Identifying those who will require specific interventions early in the progression of the disease might help to avoid adverse outcomes. Moreover, the identification of those who are likely to recover without intensive care might be useful in planning resource-allocation. This is particularly true in older patients; while chronological age is still used as a marker of health and a decision-making tool, there is strong evidence that frailty, multimorbidity, and other geriatric syndromes such as sarcopenia are better predictors of health-related outcomes in older patients 15, 16, 45 . For example, decisions about specific treatments are still often based on chronological age and the presence of one or two chronic diseases, especially in the ICUs triage. Yet, literature indicates that "high-quality care cannot be accomplished by looking only at age and diagnoses" 46,47 . In our study, patients who were transferred to the ICU were younger and non-frail. Notably, the Italian Society of Anaesthesia, Analgesia and Intensive Care (SIAARTI) released some recommendations for exceptional resource-limited situations 48 . Although the document mentions that "it might be needed to set an age limit for the admission to intensive care", it also suggests that "the presence of comorbidity and functional status must be carefully evaluated in addition to age". Our study suggests that frailty assessment should be considered.

A c c e p t e d M a n u s c r i p t 14

First, data were collected retrospectively using medical charts and electronic records and a complete comprehensive assessment of patients was not performed. Future studies should include a multidimensional evaluation including the assessment of pre-disease mobility, functional and cognitive abilities and the availability of social support. Indeed, despite the CFS is a scale widely used as a measure of frailty, it is mainly based on a functional evaluation and, as such, it may partially describe some aspects of the disability process. Thus, other frailty tools based on more objective measures should be tested in the future in order to confirm our findings. Secondly, we cannot exclude that during the severe and unexpected public health emergency, the most severely frail older patients were not even admitted to hospitals (in our sample the percentage of patients with moderate to severe frailty was 12%). Under this assumption, our results are underestimating the strength of the association, but this hypothesis should be tested in future studies. Third, we were not able to retrieve the vital status of patients transferred to the ICU, because patients needed of intensive care were transferred to other hospitals within the same or to other regions according to the availability of resources. However, sensitivity analyses, first excluding patients transferred to the ICU, and second treating transferred patients as deaths, led to comparable results. Fourth, CFS intra-or inter-observer variability was not evaluated due to limited time and resources. Fifth, the aim of our study was to investigate only in-hospital mortality and we lack data about early mortality after discharge. So, we cannot exclude the possibility that some patients may have died right after the discharge. Lastly, during the emergency, blood samples were not stored and, thus, they are not available for future analyses of biomarkers of interest, as for example inflammatory cytokines.

On the other hand, the major strengths of the study are the few missing data and the novelty of the clinical characteristics analysed; despite the small sample size the results are robust. A c c e p t e d M a n u s c r i p t 30 

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

Identification of a novel coronavirus in patients with severe acute respiratory syndrome

Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia

SARS-CoV-2 and Coronavirus Disease 2019: What We Know So Far

Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy

Prevalence of Underlying Diseases in Hospitalized Patients with COVID-19: a Systematic Review and Meta-Analysis

Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China

Frailty in elderly people

Assessing and Measuring Chronic Multimorbidity in the Older Population: A Proposal for Its Operationalization

The impact of chronic multimorbidity and disability on functional decline and survival in elderly persons. A community-based, longitudinal study

Multimorbidity and mortality in older adults: A systematic review and meta-analysis

Frailty index as a predictor of mortality: a systematic review and meta-analysis

Frailty predicts short-term survival even in older adults without multimorbidity

The impact of frailty on intensive care unit outcomes: a systematic review and meta-analysis

Social inequalities in multimorbidity, frailty, disability, and transitions to mortality: a 24-year follow-up of the Whitehall II cohort study

Frailty Hinders Recovery From Influenza and Acute Respiratory Illness in Older Adults

Frailty in people living with HIV

Joint Action ADVANTAGE WP4 Group. Frailty and Multimorbidity: A Systematic Review and Meta-analysis

Chest CT for Typical 2019-nCoV Pneumonia: Relationship to Negative RT-PCR Testing

Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review

A global clinical measure of fitness and frailty in elderly people

Guidelines for the treatment of people with COVID-19

R: A language and environment for statistical computing. R Foundation for Statistical Computing

Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China

Frailty measurement in research and clinical practice: A review

Frailty in older adults: evidence for a phenotype

Analysis of Rockwood Et Al's Clinical Frailty Scale and Fried Et Al's Frailty Phenotype as Predictors of Mortality and Other Clinical Outcomes in Older Patients Who Were Admitted to a Geriatric Ward

Association of the clinical frailty scale with hospital outcomes

Frailty and COVID-19: A Systematic Scoping Review

The effect of frailty on survival in patients with COVID-19 (COPE): a multicentre, European, observational cohort study

Frailty and sarcopenia: The potential role of an aged immune system

Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty

Inflammation and frailty in the elderly: A systematic review and meta-analysis

Impaired neutrophil extracellular trap formation: a novel defect in the innate immune system of aged individuals

COVID-19 and Multiorgan Response

Valsala Gopalakrishnan A. Coronaviruses pathogenesis, comorbidities and multi-organ damage -A review

HLH Across Speciality Collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression

Nutrition support in the time of SARS-CoV-2 (COVID-19)

A c c e p t e d M a n u s c r i p t 

The authors declared no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years, no other relationships or activities that could appear to have influenced the submitted work.